Member Info for AquaeSulis01

Phat I hope elric asks Stuart for his thoughts on why, given the difference it made to participants psoriasis, only 64% of those starting the trial with declared mild to moderate psoriasis saw the study through to its 56 day conclusion.

Remember this 3 year agreement announced 10th Sep 2018 (see RNS extract below), well things seem to be progressing nicely with lots of research sponsored by that Taiwanese company (see links)
OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, announces that it has entered into a three year non-exclusive licence agreement with Bened Biomedical Ltd., Taiwan ("Bened"). The agreement grants Bened a non-exclusive license to produce, package, promote, market, and commercialise products containing OptiBiotix's cholesterol and blood pressure reducing strain, LPLDL®, in Taiwan, with the aim of maximising the financial return for both parties.

https://www.benedbiomed.com/research
https://www.benedbiomed.com/post/psychobiotic-ps128-improves-mood-and-sleep-quality-in-its-first-clinical-study-on-anxiety-and-stress
https://www.frontiersin.org/articles/10.3389/fnut.2021.614105/full

Sounds like a great chat up line Bazz

marxist you seem to be muddling upt two different skinbiotherapeutic products. Axisbiotix is the product associated with the psoriasis study and is a blend of 6 different live probiotics. Skinbiotix is the Lacrobacillus Rhamnoses lysate and is to be commercialised as an anti-ageing ingredient

skid, SOH would not and did not provide any new information but rather emphasised the information already in the public domain. From the end Feb Commercial Update "The Company is now in a pivotal position in having a scalable business model with first generation products achieving profitability and second generation products having a solid scientific, clinical, and commercial base with early deals and open innovation projects with major corporates. With interest in the microbiome increasing, the Company is in a strong position for future growth in this exciting area of healthcare."

So the company has established its first generation products which are tipping into profit, and announcements re the second generation products which carry much higher margins will happen sooner rather than later and with the market for Cardiovascular health/Diabetes dwarfing the psoriasis market, you can do your own sums on what these deals will mean to the Opti share price but one things for sure in the not too distant future its only going one direction and that is significantly higher than today's price.

The results will be June this year as the date was slipped by 1 month in preparation for a potential NASDAQ listing.

Meantime couple of interesting tweets which suggest the delayed launches have now happened
"Multi-award-winning weight management ingredient SlimBiome and cholesterol management CholBiome finished products from OptiBiotix have recently launched into clinics, GPs and hospitals in Asia."
"CholBiome and SlimBiome brand presence grows in partnership with distribution partner UITC"
https://twitter.com/OptiBiotix

Interview out with Stuart

https://www.proactiveinvestors.co.uk/companies/news/950578/skinbiotherapeutics--delighted--with-psoriasis-study-results-with-76-reporting-less-itchy-skin-950578.html

Surprised no-one has commented on the opportunity to supply on a competitive basis graphene for Concretene which used VRS graphene for an initial pour but the process is not owned by them and has been developed to be graphene supplier independent for mass market use.

https://www.nationwideengineering.co.uk/concretene/
"We have been able to do this via thorough investigation – alongside our University colleagues from the Department of Mechanical, Aerospace and Civil Engineering – of the materials we are using and we can tailor this approach to use any supplier’s graphene, so we are not beholden to a single supplier,” he added. “This makes Concretene a more viable proposition as there is increased security of supply.”

munchbox, unfortunately you also lack class; no problem with a trader taking their profits but no need to tell all and sundry publicly and then provide a provocative sp fall prediction to LTH's who are Investors rather than traders.

Early profit takers that's all; let the market settle down and then see. As Barry White's famous song goes "A Picture Paints a Thousand Words"

Interesting Commitment to Hydrogen small vehicle transport in France

Hydrogen Mobility: Total Supports the Development of the First Hydrogen Taxi Operator in Paris
TOTAL SE
Released 07:37:00 26 May 2021
PARIS--(BUSINESS WIRE)--

Total (Paris:FP) (LSE:TTA) (NYSE:TOT) announces the acquisition of a stake in Hysetco, a French company dedicated to the development of hydrogen mobility in cities. Hysetco owns the largest fleet of hydrogen taxis in the world, launched in 2015 and operated in the Île-de-France region under the Hype brand, as well as hydrogen stations.

The Hype project aims to demonstrate for the first time on a large scale the viability of zero-emission hydrogen vehicles for urban mobility.

With the acquisition of a 20% stake, Total joins Hysetco’s historical shareholders: STEP (Société du Taxi Electrique Parisien), Air Liquide, Toyota and Kouros.

Hysetco currently owns around 700 taxis in Paris, with still a majority of diesel vehicles that will transition gradually to become exclusively comprised of hydrogen vehicles by 2024. The hydrogen taxis are fueled by a dedicated network of hydrogen stations operated by Hysetco. This network is expected to expand in the coming years to support the growth of hydrogen vehicle fleet. Total will make its network of service-stations available to Hysetco to contribute to the growth of this network of hydrogen stations.

“This acquisition is a concrete commitment and an acceleration for Total in hydrogen mobility. We are delighted to be working with partners whose skills and expertise complement each other throughout the hydrogen vehicle value chain,” declared Patrick Pouyanné, Chairman and CEO of Total. “After investing in the new Bélib’ network of charge points for electric vehicles, Total is contributing to position Paris as a showcase for new carbon-neutral urban mobility for businesses and consumers. Total is thus continuing to accelerate its transformation into TotalEnergies, a leading broad-energy

Thomas when the time comes coca cola can bid alongside Pepsi for access to s weetbiotix which a attracts a green label rating or lose out big time I would suggest. "The health effects of artificial sweeteners are controversial, and concern regarding their safety is growing (2Trusted Source). https://www.healthline.com

Though the research is inconsistent, some studies find that the use of artificial sweeteners may contribute to the development of obesity and metabolic syndrome, a cluster of conditions that increase disease risk (3Trusted Source, 4Trusted Source, 5Trusted Source).

Coca-Cola Zero Sugar (Coke Zero) uses several common artificial sweeteners, including aspartame and acesulfame potassium (Ace-K). The remaining ingredients are carbonated water, caramel color, food additives, and natural flavors (1)."

How can concretene = nanene when anyone's graphe ne can be used?"We have been able to do this via thorough investigation - alongside our University colleagues from the Department of Mechanical, Aerospace and Civil Engineering - of the materials we are using and we can tailor this approach to use any supplier's graphene, so we are not beholden to a single supplier," he added. "This makes Concretene a more viable proposition as there is increased security of supply.""

thomas, all those years of cryogenic freezing appear to have impacted your communication skills, either that or interpretive text strikes again. What was that comment in English again?

lol, I see the Green Box is still causing controversy with his vacuous commnets

No Zeon, because the Commercial Partner will decide, having successfully mass produced the ingredient, which B2B partners it invites for first mover advantage, not Opti. "SweetBiotix® is a family of products based on the concept of creating a sweet fibre that has a low glycaemic index, which enhances the microbiome. The concept uses new science, new manufacturing processes, and is a step change from existing products on the market or known to be under development. There are currently around half a dozen types of SweetBiotix® and a couple under development. The aim is to have a broad range of products suitable for a wide range of application areas which meet the needs of multiple partners on applications as diverse as dairy, cereals and hot & cold beverages. The agreement signed post period with a US partner is a significant milestone in the commercialisation of SweetBiotix® products. The agreement, for one part of the SweetBiotix® portfolio, provides an exclusive license in return for the partner bearing all the manufacturing, marketing and commercialisation costs. This is a significant investment for our partner. In return, OptiBiotix will receive upfront, annual and product launch payments from the US partner plus royalties on all future product sales. We have also negotiated enhanced royalty payments on sales of SweetBiotix® products by our partner to 11 application/ innovation partners."

One thing to say to you zahir and your not so psychic sharefriend ; Ballards

With respect anon, Lloyds Bank is a value not a growth stock so comparison a little meaningless. I have provided the reason why I believe this particular growth stock will multibag, but like Open Orphan suddenly blossomed, not just because of its astute CEO but also being in the right place at the right time as Neal Woodford is no doubt bemoaning. This as you quite rightly point out needs positive RNS's to move the price, but be sure once they arrive, and they will, you wont want to be on the outside looking in for the sake of a penny saving on the share price

No Opp, the termites are all safe and well. kisinka is 30 km east of Lubumbashi which is 1127 km from Goma which is where the volcano is

Older, besides the commercialisation of sweetbiotix, the successful development of LPLDL® as a drug biotherapeutic would 10 bag this company
"The Company will shortly be publishing placebo controlled human studies which show LPLDL® can achieve similar reductions in total cholesterol and LDL (bad cholesterol) to statins, without any side effects. Early discussions suggest that ProBiotix's existing humans studies provide safety, tolerance, and efficacy comparable to that typically seen in a Phase II pharma study. If this is confirmed the risk, timeline, and costs to develop LPLDL® as a drug biotherapeutic is substantially reduced. Chris is currently assessing the costs and timelines to develop LPLDL® as a drug biotherapeutic and the potential to create a biotherapeutic drug division or separate Limited company to fully exploit the opportunity and potential for significant upside."
https://markets.businessinsider.com/news/stocks/hyperlipidemia-drugs-market-worth-22-6-billion-by-2022-cagr-2-3-grand-view-research-inc-1027531364
The global hyperlipidemia drugs market size is expected reach USD 22.6 billion by 2022, according to a new report by Grand View Research, Inc., expanding at a CAGR of 2.3% during the forecast period. Several factors, such as increase in target population and growth in awareness about risk of cardiovascular diseases (CVD) due to persistent hypercholesterolemia, are stoking the growth of the market.
Target population of antihyperlipidemic drugs is broadly divided into statin users and nonstatin users. The revenue share of statin users has been declining. The nonstatin users segment consists of statin intolerant and nonresponsive population as well as familial hyperlipidemia (FH) population. Nonstatin users are seeking high-efficacy alternatives and this is anticipated to boost the revenue of this segment.